Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AMAG PHARMACEUTICALS, INC.

Home Clinical Trial Sponsors and OrganizationsAMAG PHARMACEUTICALS, INC.

AMAG PHARMACEUTICALS, INC.

ACTIVE

61 Mooney St, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.amagpharma.comSubsidiary440 employeesEstablished: 1981-01-01

Also known as:

amag

Part of covis group sarl

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

81

50 active

Approvals

8

Total approvals

Agencies

2

Regulatory bodies

Founded

1981

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

30

37.0%

Phase 3

17

21.0%

Phase 2

6

7.4%

Not Applicable

3

3.7%

Phase 4

1

1.2%

Trial Status Distribution

Active, not recruiting

50

61.7%

Completed

16

19.8%

Recruiting

4

4.9%

Terminated

6

7.4%

Unknown

2

2.5%

Clinical Trials

Trials sponsored by this organization (81)

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

Active, not recruiting

Mar 2022200 participants

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Oct 202141 participants

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Sep 201975 participants

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

Active, not recruiting

Jun 2019200 participants

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Jun 2019228 participants

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

Active, not recruiting

Jun 2019200 participants

A research study to evaluate the experimental drug AMAG-423 to see how well it works and how safe it is in women who are near child birth who develop a condition called severe preeclampsia.

Active, not recruiting

Mar 2019200 participants

Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with iron deficiency anemia (IDA) or who are at risk of developing IDA, and to see how safe it is compared to another marketed iron product – iron sucrose.

Active, not recruiting

Mar 201975 participants

Page 1 of 11

Approvals

Approvals by Agency

FDA

Food and Drug Administration

7

Approvals

CANADA

Health Canada

1

Approvals

Recent Approvals

News

Formation Bio Strengthens Leadership Team with Former Pfizer and BenevolentAI Executives to Advance AI-Driven Drug Development

- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.

On this page

Overview
Clinical Trials81
Approvals8
News1

Back to Organizations